121 related articles for article (PubMed ID: 18725646)
1. Endocrine therapy and bone loss in breast cancer: time to close in the RANK(L)?
Lønning PE
J Clin Oncol; 2008 Oct; 26(30):4859-61. PubMed ID: 18725646
[No Abstract] [Full Text] [Related]
2. [Cancer treatment-induced bone loss. Treatment for breast cancer].
Yamada K; Kohno N
Clin Calcium; 2008 Apr; 18(4):507-17. PubMed ID: 18379033
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.
Ellis GK; Bone HG; Chlebowski R; Paul D; Spadafora S; Smith J; Fan M; Jun S
J Clin Oncol; 2008 Oct; 26(30):4875-82. PubMed ID: 18725648
[TBL] [Abstract][Full Text] [Related]
4. Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
Tang SC
Oncology; 2010; 79(1-2):13-26. PubMed ID: 21051913
[TBL] [Abstract][Full Text] [Related]
5. [ RANKL antibody for treatment of cancer treatment-induced bone loss (CTIBL)].
Takahashi S
Clin Calcium; 2011 Aug; 21(8):1239-47. PubMed ID: 21814031
[TBL] [Abstract][Full Text] [Related]
6. [Encounter of cancer cells with bone. Cancer treatment-induced bone loss : CTIBL].
Takahashi S
Clin Calcium; 2011 Mar; 21(3):447-53. PubMed ID: 21358067
[TBL] [Abstract][Full Text] [Related]
7. [Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
Bruhn C
Med Monatsschr Pharm; 2010 Oct; 33(10):370-5. PubMed ID: 21072910
[TBL] [Abstract][Full Text] [Related]
8. Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients.
Yee AJ; Raje NS
Clin Interv Aging; 2012; 7():331-8. PubMed ID: 22977302
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant therapy with bone-targeted agents.
Wilson C; Coleman RE
Curr Opin Support Palliat Care; 2011 Sep; 5(3):241-50. PubMed ID: 21785355
[TBL] [Abstract][Full Text] [Related]
10. The long and the short of bone therapy.
Whyte MP
N Engl J Med; 2006 Feb; 354(8):860-3. PubMed ID: 16495400
[No Abstract] [Full Text] [Related]
11. [Involvement of RANKL/RANK pathway in bone metastasis in breast cancer].
Yoneda T
Clin Calcium; 2011 Aug; 21(8):1159-66. PubMed ID: 21814020
[TBL] [Abstract][Full Text] [Related]
12. Bone health management of Australian breast cancer survivors receiving hormonal therapy.
Roberts R; Miller M; O'Callaghan M; Koczwara B
Intern Med J; 2015 Nov; 45(11):1182-5. PubMed ID: 26348867
[TBL] [Abstract][Full Text] [Related]
13. The effect of aromatase inhibitors on bone metabolism.
Folkestad L; Bjarnason NH; Bjerregaard JK; Brixen K
Basic Clin Pharmacol Toxicol; 2009 Jan; 104(1):3-10. PubMed ID: 19152547
[TBL] [Abstract][Full Text] [Related]
14. Effects of third-generation aromatase inhibitors on bone.
McCloskey E
Eur J Cancer; 2006 May; 42(8):1044-51. PubMed ID: 16554149
[TBL] [Abstract][Full Text] [Related]
15. Bone targeted therapy in breast cancer: present and future.
Huober J; Thürlimann B
Crit Rev Oncol Hematol; 2010 Apr; 74 Suppl 1():S7-10. PubMed ID: 20427030
[No Abstract] [Full Text] [Related]
16. [Effect of aromatase inhibitors on bone metabolism].
Folkestad L; Bjerregaard JK; Bjarnason NH; Brixen KT
Ugeskr Laeger; 2007 May; 169(19):1774-9. PubMed ID: 17537350
[TBL] [Abstract][Full Text] [Related]
17. Hormone- and chemotherapy-induced bone loss in breast cancer.
Coleman RE
Oncology (Williston Park); 2004 May; 18(5 Suppl 3):16-20. PubMed ID: 15202583
[TBL] [Abstract][Full Text] [Related]
18. [Drug-induced osteoporosis].
Tanaka Y
Nihon Rinsho; 2007 Oct; 65 Suppl 8():394-8. PubMed ID: 18074570
[No Abstract] [Full Text] [Related]
19. Cancer treatment-induced bone loss in breast and prostate cancer.
Saad F; Adachi JD; Brown JP; Canning LA; Gelmon KA; Josse RG; Pritchard KI
J Clin Oncol; 2008 Nov; 26(33):5465-76. PubMed ID: 18955443
[TBL] [Abstract][Full Text] [Related]
20. Denosumab findings in metastatic breast cancer.
Stopeck A
Clin Adv Hematol Oncol; 2010 Mar; 8(3):159-60. PubMed ID: 20400929
[No Abstract] [Full Text] [Related]
[Next] [New Search]
